TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Košir, Rok
AU  - Ninić, Ana
AU  - Joksić, Ivana
AU  - Antonić, Tamara
AU  - Spasojević-Kalimanovska, Vesna
AU  - Prosenc Zmrzljak, Uršula
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3979
AB  - Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Defects in trophoblast invasion, differentiation of extravillous trophoblasts and spiral artery remodeling are key factors in PE development. Currently there are no predictive biomarkers clinically available for PE. Recent technological advancements empowered transcriptome exploration and led to the discovery of numerous non-coding RNA species of which microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. They are implicated in the regulation of numerous cellular functions, and as such are being extensively explored as potential biomarkers for various diseases. Altered expression of numerous lncRNAs and miRNAs in placenta has been related to pathophysiological processes that occur in preeclampsia. In the following text we offer summary of the latest knowledge of the molecular mechanism by which lnRNAs and miRNAs (focusing on the chromosome 19 miRNA cluster (C19MC)) contribute to pathophysiology of PE development and their potential utility as biomarkers of PE, with special focus on sample selection and techniques for the quantification of lncRNAs and miRNAs in maternal circulation.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential
VL  - 22
IS  - 19
DO  - 10.3390/ijms221910652
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Stefanović, Aleksandra and Košir, Rok and Ninić, Ana and Joksić, Ivana and Antonić, Tamara and Spasojević-Kalimanovska, Vesna and Prosenc Zmrzljak, Uršula",
year = "2021",
abstract = "Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Defects in trophoblast invasion, differentiation of extravillous trophoblasts and spiral artery remodeling are key factors in PE development. Currently there are no predictive biomarkers clinically available for PE. Recent technological advancements empowered transcriptome exploration and led to the discovery of numerous non-coding RNA species of which microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. They are implicated in the regulation of numerous cellular functions, and as such are being extensively explored as potential biomarkers for various diseases. Altered expression of numerous lncRNAs and miRNAs in placenta has been related to pathophysiological processes that occur in preeclampsia. In the following text we offer summary of the latest knowledge of the molecular mechanism by which lnRNAs and miRNAs (focusing on the chromosome 19 miRNA cluster (C19MC)) contribute to pathophysiology of PE development and their potential utility as biomarkers of PE, with special focus on sample selection and techniques for the quantification of lncRNAs and miRNAs in maternal circulation.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential",
volume = "22",
number = "19",
doi = "10.3390/ijms221910652"
}

Munjas, J., Sopić, M., Stefanović, A., Košir, R., Ninić, A., Joksić, I., Antonić, T., Spasojević-Kalimanovska, V.,& Prosenc Zmrzljak, U.. (2021). Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential. in International Journal of Molecular Sciences
MDPI., 22(19).
https://doi.org/10.3390/ijms221910652

Munjas J, Sopić M, Stefanović A, Košir R, Ninić A, Joksić I, Antonić T, Spasojević-Kalimanovska V, Prosenc Zmrzljak U. Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential. in International Journal of Molecular Sciences. 2021;22(19).
doi:10.3390/ijms221910652 .

Munjas, Jelena, Sopić, Miron, Stefanović, Aleksandra, Košir, Rok, Ninić, Ana, Joksić, Ivana, Antonić, Tamara, Spasojević-Kalimanovska, Vesna, Prosenc Zmrzljak, Uršula, "Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential" in International Journal of Molecular Sciences, 22, no. 19 (2021),
https://doi.org/10.3390/ijms221910652 . .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Joksić, Ivana
AU  - Prosenc Zmrzljak, Ursula
AU  - Karadžov-Orlić, Nataša
AU  - Košir, Rok
AU  - Egić, Amira
AU  - Miković, Željko
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3669
PB  - Elsevier
T2  - Clinical Biochemistry
T1  - Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]
VL  - 85
SP  - 57
EP  - 57
DO  - 10.1016/j.clinbiochem.2020.08.011
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Joksić, Ivana and Prosenc Zmrzljak, Ursula and Karadžov-Orlić, Nataša and Košir, Rok and Egić, Amira and Miković, Željko and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2020",
publisher = "Elsevier",
journal = "Clinical Biochemistry",
title = "Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]",
volume = "85",
pages = "57-57",
doi = "10.1016/j.clinbiochem.2020.08.011"
}

Munjas, J., Sopić, M., Joksić, I., Prosenc Zmrzljak, U., Karadžov-Orlić, N., Košir, R., Egić, A., Miković, Ž., Ninić, A.,& Spasojević-Kalimanovska, V.. (2020). Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]. in Clinical Biochemistry
Elsevier., 85, 57-57.
https://doi.org/10.1016/j.clinbiochem.2020.08.011

Munjas J, Sopić M, Joksić I, Prosenc Zmrzljak U, Karadžov-Orlić N, Košir R, Egić A, Miković Ž, Ninić A, Spasojević-Kalimanovska V. Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]. in Clinical Biochemistry. 2020;85:57-57.
doi:10.1016/j.clinbiochem.2020.08.011 .

Munjas, Jelena, Sopić, Miron, Joksić, Ivana, Prosenc Zmrzljak, Ursula, Karadžov-Orlić, Nataša, Košir, Rok, Egić, Amira, Miković, Željko, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]" in Clinical Biochemistry, 85 (2020):57-57,
https://doi.org/10.1016/j.clinbiochem.2020.08.011 . .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Joksić, Ivana
AU  - Prosenc Zmrzljak, Ursula
AU  - Karadžov-Orlić, Nataša
AU  - Košir, Rok
AU  - Egić, Amira
AU  - Miković, Željko
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3602
AB  - Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p.
PB  - Elsevier
T2  - Clinical Biochemistry
T1  - Placenta-specific plasma miR518b is a potential biomarker for preeclampsia
VL  - 79
SP  - 28
EP  - 33
DO  - 10.1016/j.clinbiochem.2020.02.012
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Joksić, Ivana and Prosenc Zmrzljak, Ursula and Karadžov-Orlić, Nataša and Košir, Rok and Egić, Amira and Miković, Željko and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p.",
publisher = "Elsevier",
journal = "Clinical Biochemistry",
title = "Placenta-specific plasma miR518b is a potential biomarker for preeclampsia",
volume = "79",
pages = "28-33",
doi = "10.1016/j.clinbiochem.2020.02.012"
}

Munjas, J., Sopić, M., Joksić, I., Prosenc Zmrzljak, U., Karadžov-Orlić, N., Košir, R., Egić, A., Miković, Ž., Ninić, A.,& Spasojević-Kalimanovska, V.. (2020). Placenta-specific plasma miR518b is a potential biomarker for preeclampsia. in Clinical Biochemistry
Elsevier., 79, 28-33.
https://doi.org/10.1016/j.clinbiochem.2020.02.012

Munjas J, Sopić M, Joksić I, Prosenc Zmrzljak U, Karadžov-Orlić N, Košir R, Egić A, Miković Ž, Ninić A, Spasojević-Kalimanovska V. Placenta-specific plasma miR518b is a potential biomarker for preeclampsia. in Clinical Biochemistry. 2020;79:28-33.
doi:10.1016/j.clinbiochem.2020.02.012 .

Munjas, Jelena, Sopić, Miron, Joksić, Ivana, Prosenc Zmrzljak, Ursula, Karadžov-Orlić, Nataša, Košir, Rok, Egić, Amira, Miković, Željko, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Placenta-specific plasma miR518b is a potential biomarker for preeclampsia" in Clinical Biochemistry, 79 (2020):28-33,
https://doi.org/10.1016/j.clinbiochem.2020.02.012 . .